Market Place
Sourcing Support
BlackThorn Advances Phase 2 Clinical Development for Selective KOR Antagonist
23 Jan 2020 //
BIO SPACE
Polaris Partners — maps $400M for ninth fund
20 Jun 2019 //
ENDPTS
BlackThorn bags $76M to push targeted treatments for brain disorders
13 Jun 2019 //
FIERCE BIOTECH
BlackThorn Announces Positive Ph 1 Results KOR Antagonist, BTRX-335140
01 Apr 2019 //
BUSINESSWIRE
Biomatics raises $300M for healthcare fund, recruits biopharma veterans
08 Nov 2018 //
FIERCE BIOTECH
BlackThorn Therapeutics Names Bill Martin, Ph.D., President and Chief Operating Officer
08 Nov 2018 //
BUSINESSWIRE
Jnana President Joanne Kotz to take on CEO role
07 Nov 2018 //
FIERCE BIOTECH
BlackThorn Announces Exclusive Licensing Agreement & Yale University
06 Aug 2018 //
PRESS RELEASE
BlackThorn Therapeutics Names George S. Golumbeski, Ph.D., to Board of Directors
12 Jun 2018 //
PRESS RELEASE
BlackThorn Initiates Ph1 Study of BTRX-335140, Investigational (KOR) Antagonist
06 Jun 2018 //
PRESS RELEASE
BlackThorn Presents Pre & Clinical Data from Its First-in-Class NOPR Antagonist
07 Dec 2017 //
PRESS RELEASE
BlackThorn`s Presents Preclinical & Clinical Data From Its First-in-Class NOPR
07 Dec 2017 //
BUSINESSWIRE
BlackThorn Enrolls First Patient in Ph2a Study of Lead Compound, BTRX-246040
24 Jul 2017 //
PRESS RELEASE
BlackThorn Enrolls First Patient in Ph 2a Study of Lead Compound, BTRX-246040
24 Jun 2017 //
PRESS RELEASE
BlackThorn To Receive Up to $8 M in NIH Blueprint Neurotherapeutics
20 Jun 2017 //
PRESS RELEASE
BlackThorn Announces Innovative Clinical Collab Agreement with Mindstrong Health
07 Jun 2017 //
BUSINESSWIRE
BlackThorn Announces Innovative Clinical Collab Agreement Mindstrong Health
07 Jun 2017 //
PRESS RELEASE
BlackThorn Announces Results of Preclinical Study of BTRX-335140
06 Apr 2017 //
PRESS RELEASE
BlackThorn Therapeutics bring in new CEO
20 Feb 2017 //
PHARMAFILE
BlackThorn Therapeutics Secures $14 Million in Series A Extension Financing
05 Jan 2017 //
PRESS RELEASE
Arch, J&J Join $40M Bet on New Approach to Neurobehavioral Drug Discovery
20 Oct 2016 //
PRESS RELEASE
J&J backs neuro startup BlackThorn in $40M Series A
20 Oct 2016 //
FIERCE BIOTECH
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.